Imagine there’s a new drug on the market to treat obesity. Problem is, tests have shown that it causes kidney failure in 7 percent of patients. The company marketing the drug ran tests that showed the kidney failure risk, but didn’t make the risk public. Now imagine there’s a law that would force the drug company to tell the public about every test it conducted on the drug.
If certain policymakers and interest groups get their way, such a law could soon become a reality. While this law would be a boon for doctors and patients alike, pharmaceutical companies need to keep a watchful eye on how this could affect their patent rights.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]